Introduction
In assisted reproductive technology (ART), patients classified as "poor ovarian responders" (POR) present a significant clinical challenge. These individuals produce very few oocytes during a stimulation cycle. When only one or two oocytes are retrieved, the risk of total fertilization failure (TFF) is high, potentially leading to the loss of the entire treatment cycle.
To mitigate this risk, many clinicians opt for Intracytoplasmic Sperm Injection (ICSI)—where a single sperm is injected directly into the oocyte—even in the absence of male-factor infertility. The assumption is that ICSI provides a "safety net" to ensure fertilization. However, recent evidence suggests that for non-male factor cases, ICSI may not offer the expected benefits and could even be detrimental. This study evaluates whether ICSI truly improves outcomes for patients at the extreme end of the poor-response spectrum.
Methods
This retrospective study analyzed 2,572 patients treated at Xiamen University Affiliated Chenggong Hospital between 2013 and 2022. Inclusion criteria were limited to patients with only 1 or 2 retrieved oocytes and no severe male factor infertility.
The initial cohort consisted of 2,159 patients in the conventional IVF group and 413 in the ICSI group. To account for baseline differences and potential selection bias, the researchers employed Propensity Score (PS) matching. This process created balanced groups of 401 patients each, allowing for a more rigorous comparison of clinical outcomes.
Key Results
The study revealed several critical differences in outcomes between the two insemination methods:
- Fertilization Rates: Contrary to the "safety net" hypothesis, the ICSI group experienced a significantly higher rate of Total Fertilization Failure (TFF) compared to the IVF group (P < 0.05). The adjusted odds ratio for TFF was 1.65, indicating that ICSI patients were 65% more likely to have no successful fertilization.
- Pregnancy Outcomes: In the matched cohort, the cumulative pregnancy rate per initiated cycle was significantly higher in the IVF group (28.7%) than in the ICSI group (21.7%, P=0.028).
- Live Birth Rates: While the cumulative live birth rate (CLBR) was higher in the IVF group (21.2% vs. 17.2%), this difference did not reach statistical significance (P = 0.179). However, the adjusted odds ratio of 0.76 suggests a trend favoring conventional IVF.
- Embryo Quality: Interestingly, once fertilization was achieved, the quality of the resulting embryos was comparable between the two groups, suggesting that the negative impact of ICSI is localized to the fertilization stage itself.
Discussion: The ICSI Paradox
The finding that ICSI leads to higher failure rates in poor responders is counterintuitive but may be explained by several biological factors:
- Maturation Timing and Denudation: ICSI requires "denudation," the removal of cumulus cells surrounding the oocyte. These cells are essential for the final stages of oocyte maturation. Removing them too early may disrupt the delicate nucleus-cytoplasmic maturation process, leading to oocytes that appear mature but are functionally incapable of successful fertilization.
- Mechanical Fragility: Oocytes from poor responders may be more susceptible to mechanical stress. The physical trauma of the ICSI needle injection might cause damage that a more robust oocyte could withstand.
- Polyspermy vs. Failure: While conventional IVF had higher rates of multiple fertilization (polyspermy), the overall gain in successful fertilizations outweighed the loss of these non-viable embryos.
Conclusion
For patients with extremely poor ovarian response (1–2 oocytes) and no male-factor infertility, conventional IVF appears superior to ICSI. ICSI not only fails to prevent fertilization failure in this population but may also reduce the cumulative pregnancy rate. Clinicians should reconsider the reflexive use of ICSI as a "rescue" technique for poor responders, as the natural selection process of conventional IVF may yield better clinical outcomes. Further large-scale randomized controlled trials are needed to confirm these findings and refine treatment protocols for this vulnerable patient group.
Summary updated